Skip to main content
. 2017 Aug 8;12(8):e0182689. doi: 10.1371/journal.pone.0182689

Fig 5. Molecular imaging of tumor viability and metabolism in response to sorafenib treatment.

Fig 5

A: Images for representative mice bearing HCT116-luc2 tumors are shown that were imaged on day 9 by BLI to assess tumor burden/viability. Compared with vehicle control, HCT116-luc2 tumors treated with 120 mg/kg of sorafenib show significant quantitative reduction of BLI signal on day 9, indicating loss of tumor viability. (*p < 0.01, n = 15, student’s t-test, bar: s.e.m., representative of three independent studies) B: Images of tumor-bearing mice imaged using fluorescent BRS-680 and TfV-750. Both probes were administered IV on day 8 and the animals were imaged on day 9, allowing sufficient time to generate a tumor-specific fluorescent contrast. Compared with control tumors, the sorafenib treatment significantly reduced tumor metabolic activity on day 9. (#p < 0.05, n = 5, Student’s t-test, bar: s.e.m., representative of three independent studies).